Written by the Core Power Peptides Research Team — biochemists and laboratory specialists compiling and verifying peptide research data. Learn about our quality standards →
Tesamorelin holds a distinction no other compound in its class can claim: it is the only FDA-approved GHRH analog, cleared under the brand name Egrifta in 2010 for HIV-associated lipodystrophy. That approval came with a Phase 3 dataset far deeper than most research peptides ever accumulate, which is why tesamorelin is frequently used as the reference GHRH agonist when an established comparator is needed.
Tesamorelin’s Structure and Regulatory Standing
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid group added to the N-terminus. Developed by Theratechnologies, it is the only FDA-approved GHRH analog — approved under the brand name Egrifta® for HIV-associated lipodystrophy in 2010. Beyond its approved indication, tesamorelin has attracted substantial research interest for its effects on body composition, metabolic function, and age-related growth hormone decline.
Unlike direct GH replacement, tesamorelin preserves the pulsatile pattern of endogenous GH secretion, a pharmacological advantage that researchers consider important for mimicking physiological conditions in study designs.
Mechanism of Action
Tesamorelin activates GH secretion through the hypothalamic-pituitary axis:
- GHRH Receptor (GHRHR) Agonism: Binds and activates pituitary somatotroph GHRH receptors, triggering GH synthesis and release
- cAMP Signaling: Activates adenylyl cyclase cascade, increasing intracellular cAMP and PKA activity in somatotrophs
- Preserved Pulsatility: Enhances amplitude of endogenous GH pulses rather than producing continuous supraphysiological levels
- IGF-1 Cascade: Downstream GH stimulation increases hepatic IGF-1 production, the primary mediator of GH’s anabolic effects
- Lipolytic Effects: GH-mediated activation of hormone-sensitive lipase in visceral adipose tissue, particularly relevant for lipodystrophy research
Clinical Research Data
HIV-Associated Lipodystrophy (FDA-Approved Indication)
Phase 3 trials leading to FDA approval demonstrated robust effects:
- Mean visceral adipose tissue (VAT) reduction of 15–20% from baseline at 26 weeks vs. placebo
- Significant improvements in trunk fat ratio and waist circumference
- Trunk-to-limb fat ratio improved vs. stable placebo group
- Benefits observed across HIV-positive patients on antiretroviral therapy
Age-Related GH Decline Research
Studies in healthy older adults (60+ years) have investigated tesamorelin for somatopause:
- IGF-1 levels increased to levels comparable to those of young adults in multiple trials
- Improved lean mass and reduced total body fat in 6-month protocols
- Improvements in cognitive function (verbal memory, executive function) observed in a 2019 randomized trial (n=152 older adults with mild cognitive impairment)
- Favorable changes in cardiovascular risk markers including triglycerides and LDL in metabolic sub-studies
NAFLD/Metabolic Research
- Pilot studies show tesamorelin reduces liver fat fraction in patients with non-alcoholic fatty liver disease
- Improved hepatic insulin sensitivity markers in metabolic syndrome research
Dosage Reference for Research
| Study Context |
Dose |
Frequency |
Duration |
| FDA-approved (lipodystrophy) |
2mg |
Daily SC |
26+ weeks |
| Aging/cognitive research (human) |
1–2mg |
Daily SC |
20–26 weeks |
| Rodent models |
100–300 µg/kg |
Daily SC |
4–12 weeks |
Research reference only. Not dosing guidance for human use.
Tesamorelin vs. CJC-1295 — Research Comparison
| Parameter |
Tesamorelin |
CJC-1295 (Without DAC) |
| Sequence |
Full GHRH (44 aa) + trans-3-hexenoic acid |
Modified GHRH 1-29 (30 aa) |
| FDA approval |
Yes (Egrifta — HIV lipodystrophy) |
No |
| Half-life |
~26 minutes |
~30 minutes (without DAC) |
| Clinical data depth |
Extensive (Phase 3 + approval) |
Phase 1/2 only |
| Primary use in research |
Lipodystrophy, aging, cognition |
GH secretion, body composition |
Where to Buy Tesamorelin for Research
When sourcing tesamorelin for laboratory research, evaluate suppliers on:
- HPLC purity ≥99% with detailed COA
- Mass spectrometry confirmation of full 44-aa sequence and N-terminal modification
- Sterility and endotoxin testing documentation
- Lyophilized format for −20°C long-term stability
Tesamorelin Research Products
HPLC Verified
Tesamorelin 10mg
Purity: 99%+ HPLC
Format: Lyophilized Powder
Testing: Third-Party COA
$140
Buy Now
HPLC Verified
Tesamorelin 20mg
Purity: 99%+ HPLC
Format: Lyophilized Powder
Testing: Third-Party COA
$250
Buy Now
Frequently Asked Questions
Why is preserved GH pulsatility significant in research design?
Tesamorelin enhances the amplitude of endogenous GH pulses rather than producing continuous supraphysiological levels. For researchers modeling physiological conditions that distinction matters — direct GH replacement flattens the natural secretion rhythm, while a GHRH analog works through the hypothalamic-pituitary axis and leaves pulsatility intact.
How does tesamorelin compare to sermorelin?
Both are GHRH analogs acting at the same pituitary receptor, but tesamorelin is the full 44-residue sequence carrying a stabilizing N-terminal modification, while sermorelin is the truncated GRF(1-29) fragment. The tesamorelin vs sermorelin comparison covers the structural and stability differences in full.
What separates tesamorelin from CJC-1295 in practice?
Regulatory depth is the clearest difference — tesamorelin has completed Phase 3 and holds FDA approval, while CJC-1295 has Phase 1/2 data only. Half-lives are broadly comparable at roughly 26 and 30 minutes respectively for the non-DAC forms.
Compiled for educational and scientific reference. Tesamorelin from Core Power Peptides is supplied for in vitro and laboratory research exclusively — not for human consumption and not medical advice. Researchers are responsible for compliance with applicable local regulations.
